As a consequence, IL6 has emerged as a potential therapeutic target in pancreatic cancer, and a phase II clinical trial is underway aimed at evaluating the anti-tumour efficacy of tocilizumab, an anti-IL6 receptor antibody, in patients with unresectable pancreatic cancer (clinical trials.gov NCT02767557). Here, IL6 is linked to neoplasm.